Literature DB >> 8227179

Arrest of cell cycle progression of HeLa cells in the early G1 phase in K(+)-depleted conditions and its recovery upon addition of insulin and LDL.

H Yamaguchi1, K Hosokawa, Z L Jiang, A Takahashi, T Ikehara, H Miyamoto.   

Abstract

Cell cycle progression of synchronized HeLa cells was studied by measuring labeling of the nuclei with [3H]thymidine. The progression was arrested in a chemically defined medium in which K+ was replaced by Rb+ (Rb-CDM) but was restored upon addition of insulin and/or low density lipoprotein (LDL). Cells started DNA synthesis 12 hr after addition of insulin and/or LDL, regardless of the time of arrest, suggesting their arrest early in the G1 phase. After incubation of cells in Rb-CDM containing insulin or LDL singly for 3, 6, or 9 hr, replacement of the medium by that without an addition resulted in marked delay in entry of cells into the S phase, but in its replacement by medium containing both agents, the delay was insignificant. Synthesis of bulk protein, estimated as increase in the cell volume, was not strongly inhibited. From these results we conclude that cell cycle progression of HeLa cells in K(+)-depleted CDM is arrested early in the G1 phase and that the arrest is due to lack of some protein(s) required for entry into the S phase that is synthesized in the early G1 phase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227179     DOI: 10.1002/jcb.240530103

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  2 in total

1.  The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

2.  A cell cycle alteration precedes apoptosis of granule cell precursors in the weaver mouse cerebellum.

Authors:  A Migheli; R Piva; S Casolino; C Atzori; S R Dlouhy; B Ghetti
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.